Print Email

Recent Publications by Members of the Oncodermatology Study Group


Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails. Lacouture M, Sibaud V. Am J Clin Dermatol. 2018 Oct 30.

Pruritus Associated with Targeted Anticancer Therapies and Their Management. Wu J, Lacouture ME. Dermatol Clin. 2018 Jul;36(3):315-324.

A Randomized Trial of Mometasone Furoate 0.1% to Reduce High-Grade Acute Radiation Dermatitis in Breast Cancer Patients Receiving Postmastectomy Radiation. Ho AY, Olm-Shipman M, Zhang Z, Siu CT, Wilgucki M, Phung A et al. Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):325-333. Erratum in: Int J Radiat Oncol Biol Phys. 2018 Sep 1;102(1):231.

Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy. Sibaud V. Am J Clin Dermatol. 2018 Jun;19(3):345-361.

Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update. Geller S, Xu H, Lebwohl M, Nardone B, Lacouture ME, Kheterpal M. Am J Clin Dermatol. 2018 Jun;19(3):363-375.

Inflammatory dermatoses, infections, and drug eruptions are the most common skin conditions in hospitalized cancer patients. Phillips GS, Freites-Martinez A, Hsu M, Skripnik Lucas A, Barrios DM, Ciccolini K et al. J Am Acad Dermatol. 2018 Jun;78(6):1102-1109.

Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review. Lacouture ME, Anadkat M, Jatoi A, Garawin T, Bohac C, Mitchell E. Clin Colorectal Cancer. 2018 Jun;17(2):85-96. Free Article

Taking it in the chin: vitamin K1 for the prevention of acneiform rash. Lacouture ME. Ann Oncol. 2018 Apr 1;29(4):796-798.

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R et al; Society for Immunotherapy of Cancer Toxicity Management Working Group. J Immunother Cancer. 2017 Nov 21;5(1):95.

A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies. Tischer B, Bilang M, Kraemer M, Ronga P, Lacouture ME. Support Care Cancer. 2018 Apr;26(4):1169-1179.

The microbial flora of taxane therapy-associated nail disease in cancer patients. Virgen CA, Belum VR, Kamboj M, Goldfarb SB, Blinder VS, Gucalp A, Lacouture ME. J Am Acad Dermatol. 2018 Mar;78(3):607-609.

Efficacy of a global supportive skin care programme with hydrotherapy after non-metastatic breast cancer treatment: A randomised, controlled study. Dalenc F, Ribet V, Rossi AB, Guyonnaud J, Bernard-Marty C, de Lafontan B et al. Eur J Cancer Care (Engl). 2018 Jan;27(1).

Barriers and enablers to implementing scalp cooling in Australia: a qualitative study of health professionals' attitudes to and experience with scalp cooling. Shaw JM, O'Brien J, Chua S, De Boer R, Dear R, Murray N, Boyle F. Support Care Cancer. 2018 Jan;26(1):305-312.

Scalp hypothermia as a preventative measure for chemotherapy-induced alopecia: a review of controlled clinical trials. Shah VV, Wikramanayake TC, DelCanto GM, van den Hurk C, Wu S, Lacouture ME, Jimenez JJ. J Eur Acad Dermatol Venereol. 2017 Oct 4. [Epub ahead of print] Review.

Supportive Treatments for Patients with Cancer. Jordan K, Feyer P, Höller U, Link H, Wörmann B, Jahn F. Dtsch Arztebl Int. 2017 Jul 10;114(27-28):481-487. Free PMC Article

Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors. Zarbo A, Belum VR, Sibaud V, Oudard S, Postow MA, Hsieh JJ, Motzer RJ, Busam KJ, Lacouture ME. Br J Dermatol. 2017 Jun;176(6):1649-1652.

An Integrated Chemical Environment to Support 21st-Century Toxicology. Bell SM, Phillips J, Sedykh A, Tandon A, Sprankle C, Morefield SQ, Shapiro A, Allen D, Shah R, Maull EA, Casey WM, Kleinstreuer NC. Environ Health Perspect. 2017 May 25;125(5):054501.  Free PMC Article

Dermatologic events from EGFR inhibitors: the issue of the missing patient voice. Tischer B, Huber R, Kraemer M, Lacouture ME.  Support Care Cancer. 2017 Feb;25(2):651-660. Free PMC Article

Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors. Hofheinz RD, Deplanque G, Komatsu Y, Kobayashi Y, Ocvirk J, Racca P, Guenther S, Zhang J, Lacouture ME, Jatoi A. Oncologist. 2016 Dec;21(12):1483-1491.Free Full Text

Dermatological adverse events with taxane chemotherapy. Sibaud V, Lebœuf NR, Roche H, Belum VR, Gladieff L, Deslandres M, Montastruc M, Eche A, Vigarios E, Dalenc F, Lacouture ME. Eur J Dermatol. 2016 Oct 1;26(5):427-443.

Mechanisms of skin aging induced by EGFR inhibitors. Gerber PA, Buhren BA, Schrumpf H, Hevezi P, Bölke E, Sohn D, Jänicke RU, Belum VR, Robert C, Lacouture ME, Homey B. Support Care Cancer. 2016 Oct;24(10):4241-8. 

Xerosis and pruritus as major EGFRI-associated adverse events. Clabbers JMK, Boers-Doets CB, Gelderblom H, Stijnen T, Lacouture ME, van der Hoeven KJM, Kaptein AA. Support Care Cancer. 2016 Feb;24(2):513-521. Free Full Text

Acquired perforating dermatosis associated with sorafenib therapy. Severino-Freire M, Sibaud V, Tournier E, Pauwels C, Christol C, Lamant L, Hautier-Mazeereuw J, Peron JM, Paul C, Bulai Livideanu C. J Eur Acad Dermatol Venereol. 2016 Feb;30(2):328-30.

Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis. Belum VR, Serna-Tamayo C, Wu S, Lacouture ME. Clin Exp Dermatol. 2016 Jan;41(1):8-15. Free Full Text

Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management. McLellan B, Ciardiello F, Lacouture ME, Segaert S, Van Cutsem E. Ann Oncol. 2015 Oct;26(10):2017-26. Free Full Text

A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies. Chan A, Cameron MC, Garden B, Boers-Doets CB, Schindler K, Epstein JB, Choi J, Beamer L, Roeland E, Russi EG, Bensadoun RJ, Teo YL, Chan RJ, Shih V, Bryce J, Raber-Durlacher J, Gerber PA, Freytes CO, Rapoport B, LeBoeuf N, Sibaud V, Lacouture ME. Support Care Cancer. 2015 Aug;23(8):2231-44.

Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis. Belum VR, Washington C, Pratilas CA, Sibaud V, Boralevi F, Lacouture ME. Pediatr Blood Cancer. 2015 May;62(5):798-806. Free Full Text

Management of dermatologic toxicities. Lacouture ME. J Natl Compr Canc Netw. 2015 May;13(5 Suppl):686-9.

Incidence and risk of xerosis with targeted anticancer therapies. Valentine J, Belum VR, Duran J, Ciccolini K, Schindler K, Wu S, Lacouture ME. J Am Acad Dermatol. 2015 Apr;72(4):656-67.

Eruptive nevi and hair depigmentation related to regorafenib. Sibaud V, Munsch C, Lamant L. Eur J Dermatol. 2015 Jan-Feb;25(1):85-6.

Overview and management of dermatologic events associated with targeted therapies for medullary thyroid cancer. Lacouture ME, Ciccolini K, Kloos RT, Agulnik M. Thyroid. 2014 Sep;24(9):1329-40.  Free Full Text

Ipilimumab in patients with cancer and the management of dermatologic adverse events. Lacouture ME, Wolchok JD, Yosipovitch G, Kähler KC, Busam KJ, Hauschild A. J Am Acad Dermatol. 2014 Jul;71(1):161-9.

Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma. Lacouture ME, Davis ME, Elzinga G, Butowski N, Tran D, Villano JL, DiMeglio L, Davies AM, Wong ET. Semin Oncol. 2014 Jun;41 Suppl 4:S1-14.

Life-threatening dermatologic adverse events in oncology. Rosen AC, Balagula Y, Raisch DW, Garg V, Nardone B, Larsen N, Sorrell J, West DP, Anadkat MJ, Lacouture ME. Anticancer Drugs. 2014 Feb;25(2):225-34. Free Full Text